Heron Therapeutics outlines $173M-$183M 2026 sales targets amid acute care momentum and expanded commercial investment
Source: SeekingAlpha
2026-02-26 15:09:33 ET
More on Heron Therapeutics
- Heron Therapeutics, Inc. (HRTX) Q4 2025 Earnings Call Transcript
- Heron Therapeutics, Inc. 2025 Q4 - Results - Earnings Call Presentation
- Heron: Near The Bottom Of A Trading Range Despite Positives
- Heron Therapeutics reports mixed Q4 results; introduces FY26 outlook
- Heron rises as preliminary revenue figures exceed estimates
Read the full article on Seeking Alpha
For further details see:
Heron Therapeutics outlines $173M–$183M 2026 sales targets amid acute care momentum and expanded commercial investment
Heron Therapeutics Inc.
NASDAQ: HRTX
HRTX Trading
5.79% G/L:
$1.01 Last:
688,499 Volume:
$0.997 Open:
HRTX Latest News
February 26, 2026 08:00:00 am
Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results
February 17, 2026 08:30:00 am
Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
HRTX Stock Data
$236,537,653
140,510,701
0.83%
62
N/A
Biotechnology & Life Sciences
Healthcare
US
Cary
